Physician profile
Amy Lemly
NPI 1336605526
$5,800.51
in general payments reported to CMS, 2019-2025
17 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $1,269 · 2023: $1,033 · 2024: $1,566 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158 · Travel and Lodging: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,157.52 |
| Travel and Lodging | $1,935.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,721.19 | 2021-2025 | Evoque, Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $458.55 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $392.12 | 2021-2025 | Farxiga, Lokelma, Wainua |
| E.R. Squibb & Sons, L.L.C. | $306.15 | 2021-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $274.22 | 2022-2023 | Corevalve Evolut R |
| Pfizer INC. | $221.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $196.90 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $51.13 | 2021-2023 | Uptravi |
| Amgen INC. | $31.80 | 2022-2024 | Repatha |
| Novo Nordisk INC | $30.88 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $21.85 | 2025 | Evkeeza |
| Merck Sharp & Dohme LLC | $19.02 | 2025 | Verquvo |
| Abbott Laboratories | $17.08 | 2023 | Mitraclip |
| Chiesi USA, INC. | $16.39 | 2023 | Cleviprex, Kengreal |
| Alnylam Pharmaceuticals INC. | $14.56 | 2025 | Amvuttra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.63 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lemly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.